Business · 12/05/2025Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for LAMZEDE Patent Extension
Summary
The FDA has published a notice determining the regulatory review period for LAMZEDE, a human biological product, following a patent extension application submitted to the USPTO.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →